Bladder cancer

First-line therapy of synchronous and metachronous metastatic UCa

Last updated: 10.05.2024

Solve cases and receive feedback

Case 1 - ECOG PS 1, GFR 90 ml/min

Case 2 - ECOG PS 0, GFR 70 ml/min, adjuvant dd-MVAC 5 mo ago

Case 3 - ECOG PS 2, GFR 35 ml/min, grade 2 neuropathy

Case 4 - ECOG PS 1, GFR 45 ml/min, RC alone 15 mo ago

Case 5 - Stable disease after first-line GC

Case 6 - ECOG PS 1, GFR 45 ml/min, neoadjuvant GC 15 mo ago

Case 7 - ECOG PS 1, GFR 45 ml/min

Case 8 - ECOG PS 1, GFR 45 ml/min, adjuvant nivolumab

Case 9 - Complete response after first-line GemCarbo

Case 10 - ECOG PS 1, GFR 90 ml/min, FGFR2/3 wild type

Case 11 - PR after 12 cycles enfortumab vedotin + pembrolizumab

Case 12 - ECOG PS 1, GFR 48 ml/min, adjuvant nivolumab

Follow a course and earn CME credits

Earn CME credits by running a case series and completing an assessment. Many topics available for various disease areas. And all for free!

Start a course